New drug combo aims to stop immune attack after kidney transplant
NCT ID NCT05049850
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a drug called imlifidase, given with other medications, could prevent the immune system from attacking a new kidney in highly sensitized patients. These patients have a very high risk of rejecting a donated kidney. The study was stopped early after only 3 participants, so the results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health Transplant Institute
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk